Galderma Group

GALD

The current Galderma Group (GALD) market capitalization is approximately CHF38.48B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Galderma Group's market cap fluctuates with changes in its share price and share count. Last updated: January 1, 2026 at 12:03 AM Eastern Time

In the most recently reported quarter, Galderma Group (GALD) generated CHF1.03B in revenue, representing a +15.12% year over year change. For the next quarter, analyst consensus currently expects revenue of approximately CHF1.20B, implying an expected +15.11% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 3:33 AM Eastern Time

In the most recently reported fiscal year, Galderma Group (GALD) generated net income of CHF209.33M, compared with CHF-48.00M in the prior fiscal year, representing a -536.12% year over year change. For the upcoming fiscal year, analyst consensus currently estimates net income of CHF437.79M. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 3:33 AM Eastern Time

Galderma Group (GALD) is currently scheduled to report its next earnings results on March 4, 2026. Earnings dates are subject to change and may be updated by the company with limited notice. Investors typically monitor upcoming earnings releases closely, as they can result in increased volatility depending on reported results, forward guidance, and management commentary. Last updated: January 1, 2026 at 12:03 AM Eastern Time

In the most recently reported quarter, Galderma Group (GALD) revenue was CHF1.03B, compared with analyst consensus expectations of CHF993.14M, representing a +3.49% revenue surprise versus expectations. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 3:33 AM Eastern Time

Galderma Group (GALD) does not currently pay a dividend. Over the last twelve months (LTM), the company paid CHF0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 3:33 AM Eastern Time

Analyst assessments of whether Galderma Group (GALD) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: CHF162.40Consensus price target: CHF159.05Implied return: -1.88% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: January 1, 2026 at 3:33 AM Eastern Time

Based on the latest available analyst coverage, Galderma Group (GALD) currently carries a Outperform consensus rating. Analysts' average GALD price target is CHF159.05. Relative to the current share price of CHF162.40, this suggests a potential price change of approximately -1.88%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 3:33 AM Eastern Time

Like other publicly traded stocks, Galderma Group (GALD) shares are bought and sold on stock exchanges such as SWX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Galderma Group (GALD) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add GALD to your watchlist.

Galderma Group trades under the ticker symbol GALD on the SWX stock exchange. The ticker GALD is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

Galderma Group (GALD) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Galderma Group (GALD) stock peers based on overlapping products, services, and competitive dynamics:Ipsen (IPN)Puig Brands (PUIG)Beiersdorf Aktiengesellschaft (BEI)Reckitt Benckiser Group (RKT)Perrigo Company (PRGO)Sandoz Group (SDZ)UCB (UCB)Hikma Pharmaceuticals (HIK)Unilever (ULVR)Novo Nordisk (NOVO B) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Galderma Group.